for more information about stanelco click on the links.

driver's research page link
http://www.moneyam.com/InvestorsRoom/posts.php?tid=7681#lastread
website link
http://www.stanelco.co.uk/index.htm

What is and what are the advantages of a nominee account ? What about a cfd as opposed to holding actual stock

cheers

automatic
Yes you will, you will be notified when and where to sent the money so you can take up the offer.

driver
thankyou

Alan

Your last email was the most amusing I have read in a long time. I suggest you get in touch with Richard Curtis and Ben Elton with a view to writing another Blackadder masterpiece - yes who've guessed it; I am a fan of Blackadder.

I have to take up my entitlement so that I can average down. The funding is in place for Stanelco to carry on, albeit that there may be a bid. If there is then I would expect the bid price to be in excess of 0.8p. Shame, I thought I was going to do very well out of this investment. You live and learn.

Kind regards
Raymond

THS

A nominee account is one in which the named holder holds the assets in it on behalf of another (the beneficiary). In the stock market, the most common use of nominee accounts is where execution-only brokers act as nominees for their clients. The shares are registered in the name of the broker, but the client has beneficial ownership of them. The advantage of nominee accounts is that they make settlement quicker and more streamlined. In theory, dealing costs should be lower. There are some disadvantages: because the individual isn't the registered owner of the shares, he doesn't get sent company reports and accounts, and can't take advantage of shareholder perks, unless his brokers provides a special forwarding service.

CFDs (Contracts for differences) are a derivative product designed for active traders who want to have extra leverage in their share trading. Instead of paying for purchases in full, they deposit a 'margin' with their broker (typically 20% of the total purchase value) and that margin requirement goes up and down in line with the rise and fall of their portfolio. In effect, the investor is able to speculate with much more money that he actually has by borrowing from his broker and using the shares he has bought as collateral. If his investments perform well, he can get rich quicker than if he was not trading on margin. If they perform badly, the broker will demand more margin payments which have to be paid in cash, and the investor may lose significant amounts.

Contracts for differences, or margin trading, are risky, and not for novice investors. Most brokers do not offer a CFD service, and the market is dominated by a handful of brokers who specialise in this area. Margin requirements vary, and most brokers will ask for a deposit of 10,000 before allowing a new client to trade on margin.

CFDs are not my ideal way of dealing, my luck is not good enough! Most of my shares are held by NatWest Stockbrokers as nominees, it saves a hell of a lot of paperwork and makes dealing over the internet really easy.

I hope this helps.
kim

automatic - anyone

If your shares are in a PEP, SIPP or Isa A/c (all Nominee A/cs as far as the Share Registrars are concerned) you can take up entitlements but there must be available cash within the A/c.

I say this to point out that if held in (say) an ISA account which is fully invested and you have already made your full 2006/07 contribution you will have to sell something within the account to get the cash to take it up within the A/c.

But then again I could be wrong (again) and it be possible to take up an entitlement of a Isa/Sipp/Pep outside of it - but I really don't know about this.

rmhyams,
Kind words and thank you.
Alan

Thanks kim !

Kim, ths,
The Halifax offer a CFD service with a 10% margin and a minimum deposit of 1000.
Not my cup of tea, but useful to those who know how to use it!!
Alan

You are welcome ths. Thanks for that Alan; CFDs are not my cup of tea either, I can do enough damage dealing in the ordinary way!
kim

here we go...easy money!

Just to revive the French connection, but of course there may not be any relationship to SPhere, SEO have confirmed to me that is was Calyon Corporate Investment Bank to whom yesterday's RNS related.
kim

Dear Sir,

Thank you for your email.

As you probably know, Stanelco made a detailed comment on its rights and obligations concerning the JV agreement for Biotec in its RNS statement dated 9th Oct 2006 entitled " "Proposed Placing & Open Offer" .

It should be noted that the JV agreement between Sphere and Stanelco is subject to confidentiality restrictions and that the views and interpretations expressed in the above referenced RNS statement are those of Stanelco, not of Sphere;
For your convenience, please find an abstract below from the referenced RNS statement.

PS : Definition at end of RNS Statement : MAP = Modified Atmosphere Packaging, which enables a product's shelf life to be extended.

Regards


Marielle Cayron-His
Directrice de la Communication
Groupe SPHERE

Assistante de la Communication
Sandrine Bard
T. : +33 (0)1 53 65 23 00


Biotec is a subsidiary of Stanelco jointly-owned in equal shares with SPhere. The intellectual property in Biotecs products is owned by Biotec and its subsidiaries. Under the terms of the Joint Venture Agreement Stanelco and SPhere agreed that Biotec would manufacture all products to be manufactured pursuant to Biotecs IP and processes (Biotec Materials), but that the parties would be entitled to manufacture Biotec Materials themselves should the capacity of the joint venture be insufficient to meet their respective needs. In such event, Stanelco has the exclusive right to manufacture Biotec Materials relating to MAP.



Stanelco has developed various opportunities for the sale of Biotec products in the US which require the building of micro-manufacturing facilities in the US. Stanelco intends to exploit these opportunities in accordance with the provisions of the Joint Venture Agreement. As such, in the first instance these opportunities would be available to Biotec to the extent that Biotec, with the agreement of Stanelco and SPhere, is willing and able to construct facilities in the US to meet such demand. To the extent that Biotec is not able or willing to create sufficient capacity to meet this demand, Stanelco intends to do so itself in accordance with the provisions of the Joint Venture Agreement.



In order to exploit opportunities in the US relating to the manufacture of Biotec Materials relating to MAP, it will be necessary for Stanelco to make use of Biotecs intellectual property. The Joint Venture Agreement does not, however, explicitly create a licence for Stanelco to use Biotecs intellectual property nor does it expressly provide for SPhere to co-operate with Stanelco in order to procure that Biotec grants Stanelco the appropriate licence to use Biotecs intellectual property. Having taken confirmatory legal advice on the interpretation of the Joint Venture Agreement (on the basis, inter alia, that Biotec has insufficient capacity to meet Stanelcos requirements for Biotec Materials relating to MAP, particularly in the US, that it is unable or unwilling to build the facilities in the US to meet such requirements and the parties have or will have unsuccessfully tried to find alternative solutions to minimise the impact on Biotecs business in accordance with the provisions of the Joint Venture Agreement), Stanelco believes that there is an implicit obligation on SPhere to co-operate with Stanelco to pass a shareholder resolution directing Biotec Holding GmbH to grant the appropriate licence to Stanelco or to procure that the relevant Biotec entity does so.



There is, however, a risk that in such event SPhere will not co-operate with Stanelco in which case Stanelco would need to refer the matter to arbitration under the terms of the Joint Venture Agreement. In such event, there is also a risk that the arbitrator would find against Stanelco and would not oblige SPhere to co-operate in procuring that Biotec grants Stanelco the appropriate licence. In addition, unless and until such time as Stanelco obtains the appropriate licence from Biotec, there is a risk that the relevant Biotec entity will seek to bring an action against Stanelco for infringement of its intellectual property rights and that the German courts will uphold any such action.





10/10/2006 22:31
A communication@spmetal.com
cc
Objet seo







inqui

".. are those of Stanelco, not of Sphere.. "

That means Sphere do not agree, otherwise they would not have worded it thus.
Thanks, Automatic

Nice to see us above 1p.
10p next tartget?

tony
any thoughts as to what s going to happen, do you think there will be a bid for SEO, or are SEO heading for another court case, (with Sphere)

apparently SEO mentioned on CNN re new age packaging.

What?? We're gonna Greenseal a load of middle aged hippie tree huggers who think they are witches in Starpol?
Gets my vote.

Would it be off-beam to suggest that many of these AT purchases are shorts closing ?

Alfa.

Auto

Frankly, Dunno.

Sphere could possibly just be sabre rattling, with a whinge or a valid stance.

They could also be willing it down in advance of bidding. If [as ;-) ] big news is coming very soon this would be the time as the news should rapidly increase the Market Cap.

Sphere certainly would also know about, or have a good idea of, some of what is to come - through Biotec who would have been made aware of anticipated or even reserved materials requirements from SEO for MMFs in the coming year.